BrainStorm Cell Therapeutics Taps Haro Hartounian Ph.D. as COO, Effective June 18
Portfolio Pulse from Benzinga Newsdesk
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) has appointed Dr. Haro Hartounian as its new EVP and COO, effective June 18, 2024. Dr. Hartounian brings over 32 years of experience in the biopharmaceutical industry, particularly in cell and gene therapy, and will oversee all operational aspects of the company.
June 20, 2024 | 10:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BrainStorm Cell Therapeutics has appointed Dr. Haro Hartounian as its new EVP and COO, effective June 18, 2024. Dr. Hartounian's extensive experience in the biopharmaceutical industry, particularly in cell and gene therapy, is expected to enhance the company's operational efficiency and support the commercial readiness of its therapeutic platforms.
The appointment of Dr. Haro Hartounian, with his extensive experience in the biopharmaceutical industry, is likely to positively impact BrainStorm Cell Therapeutics by enhancing operational efficiency and supporting the commercial readiness of its therapeutic platforms. This strategic leadership change is expected to be well-received by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100